New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L02 ENDOCRINE THERAPY
Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.
| The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). |
L02A HORMONES AND RELATED AGENTS
Antigrowth hormones like somatostatin and octreotide, which are also used in the treatment of neoplastic diseases, are classified in H01CB.
L02AA Estrogens
Polyestradiol and combined products, which contain polyestradiol and local anestethics, are classified at the plain level L02AA02 - polyestradiol phosphate.
| ATC code | Name | DDD | U | Adm.R | Note |
| L02AA01 | diethylstilbestrol | 3 | mg | O | |
| L02AA02 | polyestradiol phosphate | 6 | mg | P | |
| L02AA03 | ethinylestradiol | 1.5 | mg | O | |
| L02AA04 | fosfestrol | 0.25 | g | O | |
| 0.25 | g | P |
Last updated: 2024-01-26